Nippon India Pharma Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (18-Jun-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹8,352 Cr
Expense Ratio
0.89%
ISIN
INF204K01I50
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
About this fund
As of 18-Jun-25, it has a Net Asset Value (NAV) of ₹563.48, Assets Under Management (AUM) of 8352.16 Crores, and an expense ratio of 0.89%.
- Nippon India Pharma Fund Direct Growth has given a CAGR return of 18.25% since inception.
- The fund's asset allocation comprises around 98.58% in equities, 0.00% in debts, and 1.42% in cash & cash equivalents.
- You can start investing in Nippon India Pharma Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.26%
+14.51% (Cat Avg.)
3 Years
+27.02%
+25.57% (Cat Avg.)
5 Years
+22.78%
+21.51% (Cat Avg.)
10 Years
+15.50%
+14.06% (Cat Avg.)
Since Inception
+18.25%
— (Cat Avg.)
Portfolio Summaryas of 31st May 2025
| Equity | ₹8,233.39 Cr | 98.58% |
| Others | ₹118.78 Cr | 1.42% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹1,049.57 Cr | 12.57% |
| Divi's Laboratories Ltd | Equity | ₹792.65 Cr | 9.49% |
| Lupin Ltd | Equity | ₹486.29 Cr | 5.82% |
| Cipla Ltd | Equity | ₹469.02 Cr | 5.62% |
| Dr Reddy's Laboratories Ltd | Equity | ₹458.21 Cr | 5.49% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹446.4 Cr | 5.34% |
| Medplus Health Services Ltd | Equity | ₹350.54 Cr | 4.20% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹311.3 Cr | 3.73% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹270.78 Cr | 3.24% |
| Narayana Hrudayalaya Ltd | Equity | ₹245.36 Cr | 2.94% |
| Gland Pharma Ltd | Equity | ₹242.95 Cr | 2.91% |
| Ajanta Pharma Ltd | Equity | ₹240.87 Cr | 2.88% |
| Abbott India Ltd | Equity | ₹239.61 Cr | 2.87% |
| Dr. Lal PathLabs Ltd | Equity | ₹197.6 Cr | 2.37% |
| Aurobindo Pharma Ltd | Equity | ₹195.43 Cr | 2.34% |
| Mankind Pharma Ltd | Equity | ₹186.93 Cr | 2.24% |
| Zydus Lifesciences Ltd | Equity | ₹186.06 Cr | 2.23% |
| Thyrocare Technologies Ltd | Equity | ₹185.27 Cr | 2.22% |
| Pfizer Ltd | Equity | ₹178.64 Cr | 2.14% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹167.57 Cr | 2.01% |
| Alkem Laboratories Ltd | Equity | ₹165.03 Cr | 1.98% |
| Sanofi India Ltd | Equity | ₹142.6 Cr | 1.71% |
| Triparty Repo | Cash - Repurchase Agreement | ₹127.3 Cr | 1.52% |
| Sai Life Sciences Ltd | Equity | ₹116.96 Cr | 1.40% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹112.57 Cr | 1.35% |
| Ipca Laboratories Ltd | Equity | ₹111.91 Cr | 1.34% |
| Suraksha Diagnostic Ltd | Equity | ₹101.78 Cr | 1.22% |
| Torrent Pharmaceuticals Ltd | Equity | ₹96.31 Cr | 1.15% |
| Fortis Healthcare Ltd | Equity | ₹77.97 Cr | 0.93% |
| Biocon Ltd | Equity | ₹76.72 Cr | 0.92% |
| Syngene International Ltd | Equity | ₹72.72 Cr | 0.87% |
| Emcure Pharmaceuticals Ltd | Equity | ₹62.54 Cr | 0.75% |
| AstraZeneca Pharma India Ltd | Equity | ₹51.08 Cr | 0.61% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹47.64 Cr | 0.57% |
| Indoco Remedies Ltd | Equity | ₹46 Cr | 0.55% |
| Orchid Pharma Ltd | Equity | ₹30.98 Cr | 0.37% |
| Concord Biotech Ltd | Equity | ₹19.54 Cr | 0.23% |
| Net Current Assets | Cash | ₹-8.58 Cr | 0.10% |
| Cash Margin - Ccil | Cash - Collateral | ₹0.06 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
36.54%
Mid Cap Stocks
31.26%
Small Cap Stocks
30.77%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹8,233.39 Cr | 98.58% |
Risk & Performance Ratios
Standard Deviation
This fund
14.97%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.13
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Fund Managers
Sailesh Raj Bhan
Since April 2005
Kinjal Desai
Since May 2018
Additional Scheme Detailsas of 31st May 2025
ISIN | INF204K01I50 | Expense Ratio | 0.89% | Exit Load | 1.00% | Fund Size | ₹8,352 Cr | Age | 12 years 5 months | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
About the AMC
Total AUM
₹6,00,436 Cr
Address
4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013
Other Funds by Nippon India Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Nippon India Pharma Fund Direct Growth?
What are the returns of Nippon India Pharma Fund Direct Growth?
What is the portfolio composition of Nippon India Pharma Fund Direct Growth?
Who manages the Nippon India Pharma Fund Direct Growth?
- Sailesh Raj Bhan
- Kinjal Desai
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.